Development of a novel mannan-based avian influenza vaccine

新型甘露聚糖禽流感疫苗的开发

• 批准号: nhmrc : 488420
• 负责人: Dr Ian Barr
• 金额: $ 13.04万
• 依托单位: Macfarlane Burnet Institute for Medical Research and Public Health
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-novel-mannan-influenza-vaccine/81684
• 关键词: Development; novel; mannan; based; avian

We have a sugar (mannan) that can be used to increase immune responses. We have found that mannan decreases the dose of inactivated virus needed for intranasal immunization. We will investigate if dose sparing is seen when given intramuscularly. This method will be first tried with the human flu virus and if successful will be tried with the bird flu virus. If the preparation can protect mice and ferrets from human or bird flu infection it could develop into a human vaccine against bird flu.

我们有一种糖（甘露聚糖）可以用来增强免疫反应。我们发现甘露聚糖降低了鼻内免疫所需的灭活病毒的剂量。我们将研究肌肉注射时是否能节省剂量。该方法将首先在人类流感病毒上进行试验，如果成功，将在禽流感病毒上进行试验。如果这种制剂可以保护小鼠和雪貂免受人类或禽流感感染，那么它就可以开发成人类针对禽流感的疫苗。